|
|
Welcome to XCELIENCE
Preformulation
At Xcelience, can tailor preformulation services to include only those pieces of information that are immediately relevant for developing a certain dosage form.
 Find out more...
Analytical and Stability
Xcelience understands early-stage development challenges, and provides a variety of dosage form options to accelerate drug development including API into capsule, API in bottle, liquid in capsule and binary blends.
Find out more...
Formulation & Pharmaceutics
Xcelience offers evaluation, development, qualification and validation of analytical methods for drug substance and drug product.
Find out more...
Manufacturing
Xcelience offers API in Capsule solutions and clinical supplies manufacturing, packaging and labeling for solids, semi-solids and non-sterile liquids.
Find out more...
|
|
|
|
|
Xcelience Makes Early Drug Development Easy
We offer pharmaceutical development solutions in
Preformulation, Formulation, Testing and Manufacturing.
Questions for Xcelience? Fill out this simple information request form and a member
of our expert drug development team will contact you within one business day.
Benefits of Xcelience
Drug Development Solutions
| √
|
|
Molecular Responsibility – At Xcelience, we believe that our first responsibility is to the molecule. Everything flows from there. We are committed to building systems and processes that reinforce quality and our ability to deliver solutions that reduce client risk and accelerate drug development.
|
| √
|
|
Expertise – Xcelience recognizes that a key component of our ability to deliver innovative solutions is the quality of our people. We value personnel who look for ways to work smarter and understand client pressures and priories.
|
| √
|
|
Access to Innovation - Xcelience has an established history of responding to client needs by adopting innovative technology and quickly building industry-leading expertise.
|
| √
|
|
Flexibility – Xcelience is a trusted partner with a unique project team structure that enables our clients to meet their critical product development and financial milestones.
|
|
|
|
|